GlassScriptPhysician profile
Mary Middagh
NPI 1396279709
$5,827.93
in general payments reported to CMS, 2019-2025
16 companies · $4,051 in 2025
The $4,051 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.40 · 2022: $699 · 2023: $555 · 2024: $479 · 2025: $4,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,096 · Food and Beverage: $2,040 · Consulting Fee: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,096.00 |
| Food and Beverage | $2,039.78 |
| Consulting Fee | $949.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,411.28 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,190.31 | 2023-2025 | Dupixent |
| Abbvie INC. | $812.86 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $487.76 | 2021-2025 | Entyvio, Eohilia |
| Enterra Medical, INC. | $390.67 | 2022 | |
| Janssen Biotech, INC. | $150.25 | 2022-2025 | Remicade, Simponi, Stelara |
| Novo Nordisk INC | $78.04 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Scientific Affairs, LLC | $66.06 | 2022 | |
| Horizon Therapeutics Plc | $61.73 | 2023 | Krystexxa |
| Ipsen Biopharmaceuticals, INC | $48.32 | 2024-2025 | Iqirvo, Dysport |
| Pfizer INC. | $32.99 | 2023-2024 | |
| Qol Medical, LLC | $28.80 | 2023 | Sucraid |
| Tersera Therapeutics LLC | $22.03 | 2025 | Xermelo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.82 | 2025 | Relistor |
| Ardelyx, INC. | $15.26 | 2025 | Ibsrela |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $13.75 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Middagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.